Oncology Research And Treatment

Herausgeber

Karger

International Standard Serial Number (ISSN )

2296-5270

ISSN gedruckt

2296-5270

Weitere Details

2024

HER receptor family synergism in the context of colorectal cancer (CRC) based on new genetic mouse models.

2023

Evaluation of single and combined SYK- and BET inhibitor inhibition in canine and human B-cell lymphoid leukaemia cell lines.

2022

Antineoplastische Effekte von Avapritinib und Nintedanib auf klonale KIT D816V+ Mastzellen in der Systemischen Mastozytose.

2022

Die doppelte Rolle von TYK2 als Onkogen und Modulator der Antitumorimmunantwort beim anaplastisch-großzelligem Lymphom.

2022

Inzidenz von COVID-19-Infektionen bei Patienten mit Mastozytose und chronischer myeloischer Leukämie im Vergleich zur Allgemeinbevölkerung in Österreich.

2022

Super-Enhancer Analyse definiert IRF4 als Zielstruktur imanaplastisch-großzelligem Lymphom und rationales Design von IRF4 Degrader Molekülen.

2020

Comparative analyses of pan- and isoform-specific BET inhibition and evaluation of synergistic potential by SYK inhibitor addition in a canine DLBCL in vitro model.

2019

Combined inhibition of BTK and PI3K acts synergistically in a canine B-cell lymphoma in vitro model.

2018

CEBPA-mutant acute myeloid leukemia is sensitive to small-molecule-mediated inhibition of the Menin-MLL interaction.

2018

Functional Investigation of SETD2 in acute myeloid leukemia.

2018

Functional cooperation of CEBPA and TET2 mutations in Acute Myeloid Leukemia.

2018

JAK1/2 inhibitor therapy-associated lymphomas in myelofibrosis arising from a preexisting B-cell clone.

2018

NUP98-rearranged acute myeloid leukemia expresses high levels of CDK6 and is hypersensitive to Palbociclib treatment.

2017

The TYK2-STAT1 pathway in aggressive T-Cell Lymphoma: A new therapeutic intervention site?

2016

The TYK2-STAT1 pathway in aggressive T-Cell Lymphoma: A new therapeutic intervention site.

2015

Evaluation of BRD4 as potential target in JAK2 V617F+MPN cells.

2015

The B-cell receptor pathway is highly actived in canine DLBCL cell line CLBL-1.

2014

Bromodomain- containing protein 4 (BRD4): a novel therapeutic target in advanced mast cell neoplasms.

2014

Effects of the multikinase inhibitor R763/AS703569 on growth and survival of neoplastic mast cells.

2014

Evaluation of the Ki-1 antigen (CD30) as a novel marker and target in advanced mastocytosis.

2014

Identification of a putative neoplastic stem cell population in human mast cell leukemia.

2014

Nilotinib exerts proatherogenic and growth-inhibitory effects on endothelial cells: a potential mechanism underlying drug-related vasculopathy in Ph plus CML.

Download
RDF/XML-Format
JSON-LD-Format
Turtle-Format
N3-Format

2024

HER receptor family synergism in the context of colorectal cancer (CRC) based on new genetic mouse models.

2023

Evaluation of single and combined SYK- and BET inhibitor inhibition in canine and human B-cell lymphoid leukaemia cell lines.

2022

Antineoplastische Effekte von Avapritinib und Nintedanib auf klonale KIT D816V+ Mastzellen in der Systemischen Mastozytose.

2022

Die doppelte Rolle von TYK2 als Onkogen und Modulator der Antitumorimmunantwort beim anaplastisch-großzelligem Lymphom.

2022

Inzidenz von COVID-19-Infektionen bei Patienten mit Mastozytose und chronischer myeloischer Leukämie im Vergleich zur Allgemeinbevölkerung in Österreich.

2022

Super-Enhancer Analyse definiert IRF4 als Zielstruktur imanaplastisch-großzelligem Lymphom und rationales Design von IRF4 Degrader Molekülen.

2020

Comparative analyses of pan- and isoform-specific BET inhibition and evaluation of synergistic potential by SYK inhibitor addition in a canine DLBCL in vitro model.

2019

Combined inhibition of BTK and PI3K acts synergistically in a canine B-cell lymphoma in vitro model.

2018

CEBPA-mutant acute myeloid leukemia is sensitive to small-molecule-mediated inhibition of the Menin-MLL interaction.

2018

Functional Investigation of SETD2 in acute myeloid leukemia.

2018

Functional cooperation of CEBPA and TET2 mutations in Acute Myeloid Leukemia.

2018

JAK1/2 inhibitor therapy-associated lymphomas in myelofibrosis arising from a preexisting B-cell clone.

2018

NUP98-rearranged acute myeloid leukemia expresses high levels of CDK6 and is hypersensitive to Palbociclib treatment.

2017

The TYK2-STAT1 pathway in aggressive T-Cell Lymphoma: A new therapeutic intervention site?

2016

The TYK2-STAT1 pathway in aggressive T-Cell Lymphoma: A new therapeutic intervention site.

2015

Evaluation of BRD4 as potential target in JAK2 V617F+MPN cells.

2015

The B-cell receptor pathway is highly actived in canine DLBCL cell line CLBL-1.

2014

Bromodomain- containing protein 4 (BRD4): a novel therapeutic target in advanced mast cell neoplasms.

2014

Effects of the multikinase inhibitor R763/AS703569 on growth and survival of neoplastic mast cells.

2014

Evaluation of the Ki-1 antigen (CD30) as a novel marker and target in advanced mastocytosis.

2014

Identification of a putative neoplastic stem cell population in human mast cell leukemia.

2014

Nilotinib exerts proatherogenic and growth-inhibitory effects on endothelial cells: a potential mechanism underlying drug-related vasculopathy in Ph plus CML.

Download
RDF/XML-Format
JSON-LD-Format
Turtle-Format
N3-Format